Neil Cashman

Company: Epifold

Job title: Chief Scientific Officer & Co-Founder

Seminars:

C-Suite Fireside Chat – Strategizing the Search for the Next ADC Target to Dominate the Limelight – Where is the Next Best Target? 9:00 am

Scoping the current state of the ADC landscape to understand the white space in target selection and the gaps to exploit Collaborating to outline the lessons learned from traditional ADC targets, including HER2, to hypothesize the qualities of a successful target Proposing the realistic expectations for ADC target selection in 2025 and earmarking the predicted…Read more

day: Conference Day One

Tumor-Specific Epitopes (TSEs) for Antibody Recognition of Misfolded Proteins 12:15 pm

Discussing how misfolding specific epitopes allow for discrimination of antibody neutralization of neurodegenerative pathogenic proteins from physiologically functional isoforms Reviewing how cell surface proteins misfold on tumor cells from aberrant cell biology and tumor bed abnormalities Unveiling how computational identification of TSEs permit generation of cancer-selective antibodies and ADCs with decreased on-target toxicity, enabling more…Read more

day: Conference Day One

Food for Artificial Thought: What are We Feeding Our Artificial Intelligence Engines? 12:45 pm

Collaborating as a community of biologists, chemists and computational scientists to highlight the strengths and limitations of implementing AI into your ADC target selection strategy Listing the required level of depth of data input needed to elicit the desired response from AI engines Adopting a premium hybrid strategy: what sections of the target selection process…Read more

day: Conference Day One